2052591-32-7
Chemical Structure
Samrotamab
Synonym(s): PR-1498487
- CAS No.: 2052591-32-7
- Formula:N/A
- Molecular Weight:(145.92 kDa)
IUPAC Name: 6-(4-aminopiperidin-1-yl)nicotinic acid hydrochloride
SMILES: [Samrotamab]
Biological Activity: Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric monoclonal antibody targeting LRRC15, with a Kd of 5.42 nM for human LRRC15. Samrotamab disrupts the LRRC15-SCG5 signaling module by binding to a membrane-proximal conformational epitope within the C-terminal leucine-rich repeat region of LRRC15, which locates at the lateral edge of the LRR solenoid while fully exposing the canonical concave β-sheet surface. Samrotamab reduces the viability of bladder cancer cells, inhibits clonogenic growth, impairs cell migration and compromises cell invasion. Samrotamab induces compensatory upregulation of LRRC15 transcripts while suppressing the expression of SCG5 mRNA. Samrotamab is applicable to research on urothelial carcinoma, sarcoma, osteosarcoma and undifferentiated pleomorphic sarcoma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Samrotamab | 96.00% | Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric monoclonal antibody targeting LRRC15, with a Kd of 5.42 nM for human LRRC15. Samrotamab disrupts the LRRC15-SCG5 signaling module by binding to a membrane-proximal conformational epitope within the C-terminal leucine-rich repeat region of LRRC15, which locates at the lateral edge of the LRR solenoid while fully exposing the canonical concave β-sheet surface. Samrotamab reduces the viability of bladder cancer cells, inhibits clonogenic growth, impairs cell migration and compromises cell invasion. Samrotamab induces compensatory upregulation of LRRC15 transcripts while suppressing the expression of SCG5 mRNA. Samrotamab is applicable to research on urothelial carcinoma, sarcoma, osteosarcoma and undifferentiated pleomorphic sarcoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Dong SW, et al. The role of LRRC15-SCG5 in ECM protein binding as a prognostic signature for urothelial carcinoma. American journal of cancer research. 2025;15(5):2301-2318. [Content Brief]
-
[2]. Wang X, et al. Cryo-EM structure of human LRRC15 reveals the basis of therapeutic antibody recognition. bioRxiv preprint. 2026.
- [3]. Demetri GD, et al. First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Jul 01;27(13):3556-3566. [Content Brief]
Keywords
